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 1 
Summary 
 
Progression through the cell cycle is strictly regulated by a number of 
regulatory proteins such as cyclins and cyclin-dependent kinases (Cdks), and 
dysregulation of cell cycle control can result in uncontrolled cell proliferation 
and tumorigenesis.  Furthermore, in response to DNA damage and 
replication stress, cells activate the DNA damage response (DDR) that 
arrests the cell cycle and stimulates DNA repair to prevent genomic 
instability.  However, if the extent of DNA damage is excessive and beyond 
the repair capacity, cells enter an irreversible cell cycle arrest (senescence) or 
apoptotic cell death.  In this study, I investigated the role of Cyclin I in cell 
cycle progression (Chapter I) and identified proline dehydrogenase (PRODH) 
as an inducer of senescence (Chapter II). 
  Chapter I has been published as follows: Nagano T, Hashimoto T, 
Nakashima A, Hisanaga S, Kikkawa U, Kamada S. Cyclin I is involved in 
the regulation of cell cycle progression. Cell Cycle 2013; 12: 2617-24. 
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Chapter I 
 
Involvement of Cyclin I in the regulation of cell cycle 
progression 
 
 
 
Abstract 
 
  Cyclins control cell cycle progression by regulating the activity of 
cyclin-dependent kinases (Cdks).  Cyclin I is a member of the cyclin family 
because of the presence of a cyclin box motif.  It has been suggested that 
Cyclin I is involved in various biological processes such as cell survival, 
angiogenesis, and cell differentiation.  However, whether or not Cyclin I has 
a role in regulating the cell cycle similarly to other cyclins has yet to be 
clarified.  Therefore, I investigated the role for Cyclin I in cell cycle 
progression.  I showed that the protein level of Cyclin I oscillated during the 
cell cycle and that Cyclin I was subjected to ubiquitination and degradation 
in cells.  The interaction between Cyclin I and Cdk5 was detected in cells 
overexpressed with both proteins.  Furthermore, depletion of Cyclin I by 
siRNAs prevented cell proliferation, suggesting the positive role of Cyclin I 
for the cell cycle progression.  In addition, flow cytometric analysis revealed 
that cells depleted of Cyclin I were accumulated at G2/M phases.  By using 
HeLa.S-Fucci (fluorescent ubiquitination-based cell cycle indicator) cells, I 
further confirmed that knockdown of Cyclin I induced cell cycle arrest at 
S/G2/M phases.  These results strongly suggest that Cyclin I has the role in 
the regulation of cell cycle progression. 
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Abbreviations 
 
Cdk: cyclin-dependent kinase 
Fucci: fluorescent ubiquitination-based cell cycle indicator 
HA: hemagglutinin 
HRP: Horseradish peroxidase 
mAG1: monomeric Azami-Green 1 
mKO2: monomeric Kusabira-Orange 2 
PBS: phosphate-buffered saline 
SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
siRNA: small interfering RNA 
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Introduction 
 
  Cyclins are the regulatory subunits of cyclin-dependent kinases (Cdks), 
and the complexes of cyclin and Cdk play key roles in the control of cell cycle 
progression.1-3  Cyclins contain a well-conserved amino acid sequence 
known as the cyclin box, which is required for the binding to and activation 
of specific target Cdks in each cell cycle phase.  Although levels of Cdks 
remain constant throughout the cell cycle, the activitiy of Cdks oscillates due 
to cell cycle-dependent phosphorylation and changes in the amounts of 
cyclins.  In addition, the ubiquitin-mediated degradation of cyclins is 
critical for proper cell cycle progression. 
  Cyclin I was originally cloned from the human forebrain cortex.4  It 
contains a typical cyclin box near the N-terminus and a PEST-rich region 
near the C-terminus, and shows the highest sequence similarity to Cyclins 
G1 and G2.  In contrast to other cyclins, the Cyclin I mRNA level does not 
fluctuate during cell cycle progression.4-6  Although the partner Cdk had not 
been identified for a long time, it has recently been reported that Cyclin I 
binds to and activates Cdk5, thereby prevents apoptosis in podocytes.6  
While most Cdks are activated in proliferating cells to promote cell cycle 
progression, the Cdk5 activity is predominantly detected in post-mitotic 
neurons7 and Cdk5 plays a role in a variety of neuronal functions such as 
neuronal development, migration, and synaptic signaling.8   
  Recent studies have suggested that Cyclin I expression is correlated with 
the proliferative activity and angiogenesis in human cancers,9, 10 and that 
increased levels of Cyclin I are associated with terminal growth arrest in 
cardiomyocytes.11  However, it is unclear whether Cyclin I has a direct role 
in regulating cell proliferation similar to other cyclins.  Therefore, I 
investigated the function of Cyclin I in the regulation of cell cycle progression.  
I report here that the protein level of Cyclin I increased during S phase and 
that Cyclin I was ubiquitinated and degraded by the proteasome in cells.  
Furthermore, knockdown of Cyclin I prevented cell proliferation through the 
cell cycle arrest at S and G2/M phases.  These results suggest that Cyclin I 
is involved in cell cycle progression. 
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Materials and Methods 
 
Antibodies. 
  Anti-Cyclin I antibody was generated by immunization of rabbits with 
synthetic peptide, CVFRLHPSSVPGPDFSKD, corresponding to the 
sequence of amino acids 276 to 292, in which the N-terminal cysteine residue 
was added to allow the conjugation of the peptide to the carrier protein upon 
immunization.  The 42-kDa band consistent with the predicted molecular 
weight of Cyclin I was detected on immunoblot analysis with this antibody.  
Anti-Flag monoclonal antibody (F3165), anti-Flag polyclonal antibody 
(F7425), and anti--tubulin monoclonal antibody (T6199) were obtained from 
Sigma Aldrich; Horseradish peroxidase (HRP)-conjugated anti-rabbit 
antibody (W4011) and HRP-conjugated anti-mouse antibody (W4021) were 
from Promega; anti-Cdk5 polyclonal antibody (sc-173) and HRP-conjugated 
anti-rat antibody (sc-2032) were from Santa Cruz Biotechnology; anti-DsRed 
polyclonal antibody (632496) was from Clontech; anti--actin monoclonal 
antibody (#3700) was from Cell Signaling Technology; anti-HA monoclonal 
antibodies (1666606 and 1867423) were from Roche; anti-Cyclin E 
monoclonal antibody (551160) was from BD Biosciences; anti-Cyclin B1 
monoclonal antibody (K0128-3) was from Medical and Biological 
Laboratories.   
 
Plasmid constructions. 
  The Cyclin I cDNA fragment corresponding to the amino acid sequence of 
full-length human Cyclin I (NCBI accession number NP_006826.1) was 
amplified from a human thymus cDNA library with the primers, 
5’-CGCTCGAGCCACCATGAAGTTTCCAGGGCCT-3’ and 
5’-CGCTCGAGCTACATGACAGAAACAGG-3’.  The resultant fragment was 
cloned into the Xho I site of pBluescript SK(-) (Stratagene) and sequenced, 
and then cloned into the Xho I site of pDsRed-Monomer-C1 (BD Biosciences) 
to construct pDsRed-Cyclin I.  For construction of Flag-tagged Cyclin I 
expression plasmid, the Cyclin I cDNA was amplified with a pair of primers 
(a forward primer: 5’-CGCTCGAGATCTAAGTTTCCAGGGCCTT-3’ and a 
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reverse primer: 5’-CGCTCGAGATCTACATGACAGAAACAGG-3’), using 
Cyclin I cDNA cloned in pBluescript SK(-) as a template, and cloned into the 
Bgl II site of a pTB701-Flag to generate pTB701-Flag-Cyclin I.  The 
fragment of PEST motif-deleted Cyclin I (Cyclin I-PEST; amino acids 1 to 
279) was amplified with the same forward primer and a reverse primer 
5’-CGTGCTCGAGATCTATAATCTGAACACTCCT-3’.  Hemagglutinin 
(HA)-tagged ubiquitin expression plasmid, pCGN-HA-ubiquitin, was kindly 
provided by M. Nakao (Kumamoto University).  Construction of HA-tagged 
Cdk5 expression plasmid, pcDNA3-HA-Cdk5, was described previously.12 
 
Cell culture, transfection, and synchronization. 
  HeLa (a cervical carcinoma cell line) cells were a gift from Dr. H. Sakamoto 
(Kobe University).  HEK293T (a human embryonic kidney cell line) cells 
were purchased from Thermo Scientific Open Biosystems.  HeLa.S-Fucci13 
cells were obtained from Riken Cell Bank.  HeLa, HEK293T, and 
HeLa.S-Fucci cells were cultured in DMEM supplemented with 10% fetal 
bovine serum.  Transfection was performed using FuGENE HD (Promega) 
or Lipofectamine (Invitrogen) according to the manufacturer’s instructions.  
Lactacystin was purchased from Calbiochem and used at the final 
concentration of 10 g/ml.  For synchronization at late G1 phase, HeLa cells 
were seeded at a density of 3 x 105 cells per 60-mm dish and cultured for 24 h.  
After exposure to 2 mM thymidine for 18 h, cells were washed with 
phosphate-buffered saline (PBS) and incubated in fresh medium for 10 h, 
and then exposed to 2 mM thymidine again for 12 h.  To release cells from 
the late G1 arrest, cells were washed with PBS, and incubated in fresh 
medium for different times. 
 
Immunoblot analysis. 
  Cells were lysed in lysis buffer [1% Nonidet P-40, 50 mM Tris-HCl (pH 7.5), 
5 mM EDTA, 150 mM NaCl, 20 mM NaF, 10 g/ml leupeptin, 10 g/ml 
aprotinin, 10 g/ml phenylmethanesulfonyl fluoride, 10 M MG132].  The 
lysates and the immunoprecipitates were separated by SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) and blotted onto Immobilon polyvinylidene 
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difluoride membrane (Millipore).  Each protein was detected using primary 
antibodies, HRP-conjugated secondary antibodies, and the ECL detection 
reagent (GE Healthcare). 
 
Immunoprecipitation. 
  For immunoprecipitation experiments, cells were lysed in lysis buffer 
supplemented with 1mM dithiothreitol, which prevents oxidation-induced 
nonspecific protein precipitation during immunoprecipitation.  Lysates 
were incubated with 5% (vol/vol) anti-Flag M2 agarose beads (Sigma Aldrich) 
or anti-HA monoclonal antibody together with protein G Sepharose (GE 
Healthcare) for 2 h at 4℃ with constant rotation.  The bound proteins were 
eluted by addition of 250 g/ml Flag peptide or 1 mg/ml HA 
peptide-containing lysis buffer.  Cell lysates and the eluates were separated 
by SDS-PAGE and immunoblotted with the indicated antibodies.  For 
analysis of the binding of Cyclin I to Cdk5, cells were extracted by sonication 
in lysis buffer without Nonidet P-40 because it has been reported that 
Cdk5-p39 complex is dissociated by the use of non-ionic detergent.14  
 
Immunofluorescence. 
  For immunofluorescence analysis, cells were fixed with 4% formaldehyde 
in PBS, permeabilized in 0.5% TritonX-100, and then incubated with 
primary antibodies in Can Get Signal immunostain Solution B (TOYOBO) 
overnight at 4℃ and incubated with Alexa Fluor 488- and Alexa Fluor 
546-conjugated secondary antibodies (Molecular Probes) for 1 h at room 
temperature.  After staining nuclei with Hoechst 33258, cells were 
examined under fluorescence microscope (model BZ-8000; Keyence). 
 
RNA interference. 
  siRNAs for Cyclin I (Hs_CCNI_1 SI00339969, Hs_CCNI_3 SI00339983, 
Hs_CCNI_4 SI00339990, and Hs_CCNI_5 SI03246334) and control siRNA 
were obtained from Qiagen.  For efficient gene silencing, siRNAs were 
transfected twice.  HeLa or HeLa.S-Fucci cells were seeded and transfected 
with 30 nM siRNAs using siPORT NeoFX Transfection Agent (Applied 
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Biosystems) according to the manufacturer’s instruction.  After incubation 
for 24 h, second transfection was performed using HiPerFect Transfection 
Reagent (Qiagen) according to the manufacturer’s instruction. 
 
Cell proliferation assay. 
  Cell proliferation reagent WST-1 (Roche) was used as the index of cell 
proliferation according to the manufacture’s instruction.  In brief, HeLa 
cells were plated at 2 x 103 cells per well in a 96-well plate and incubated for 
different days, followed by the addition of WST-1 reagent to medium and 
additional incubation for 1 h.  The cleavage of the tetrazolium salt WST-1 
by mitochondrial dehydrogenases was measured by absorbance at 450 nm 
with a reference wavelength of 650 nm. 
 
Flow cytometry. 
  HeLa cells were incubated with 0.5 ml of PI/RNase buffer (BD Biosciences) 
after fixation with 70% ethanol at -30℃, and the DNA content was measured 
using FACSCalibur (Becton-Dickinson).  1 x 104 events were analyzed for 
each sample and the data were plotted using CellQuest software 
(Becton-Dickinson). 
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Results 
 
The protein level of Cyclin I oscillates during the cell cycle. 
  It has been suggested that the levels of many proteins involved in the cell 
cycle regulation are controlled by the ubiquitin-proteasome system.1-3  
Although it was reported that the Cyclin I mRNA level did not change during 
cell cycle progression,4-6 the protein level of Cyclin I during the cell cycle 
remains unclear.  Therefore, I examined whether Cyclin I was regulated 
during the cell cycle at the protein level.  After synchronization of HeLa 
cells at late G1 phase with a double-thymidine block followed by the release 
into the cell cycle, cells were collected at various time points and analyzed by 
immunoblotting (Fig. 1).  The cells harvested at the indicated times were 
classified into respective cell cycle phase according to the protein levels of 
Cyclin E as a G1/S-phase marker, and Cyclin B1 as a G2/M-phase marker.  
Although the level of Cyclin I was low at the border of G1 and S phases, the 
protein was upregulated during S phase and gradually decreased during G2, 
M, and G1 phases.  As it has been reported that Cdk5 is a binding partner 
of Cyclin I and promotes cell survival,15 I analyzed the protein level of Cdk5 
during cell cycle progression.  The Cdk5 protein was constantly detected 
during G1, S, and G2 phases, while the level of Cdk5 was slightly decreased 
during M and early G1 phases, indicating that Cdk5 largely unchanged with 
cell cycle.  These results suggested that the protein level of Cyclin I 
oscillates during cell cycle progression partially overlapping with Cdk5 in 
particular at S phase. 
 
Cyclin I is degraded via the ubiquitin-proteasome pathway. 
  Cyclin I contains the C-terminal PEST motif (amino acids 280 to 364)4 
known as a destabilization domain,16 and the protein level of Cyclin I 
decreased at M and early G1 phases (Fig. 1).  Most proteins with a very 
short half-life including cyclins are degraded by the ubiquitin-proteasome 
system.17, 18  Therefore, I tested if Cyclin I is degraded via the 
ubiquitin-proteasome pathway.  HEK293T cells were transiently 
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transfected with pDsRed-Cyclin I and treated with or without proteasome 
inhibitor, lactacystin, for 24 h (Fig. 2A).  DsRed-Cyclin I positive cells were 
apparently increased by the treatment with lactacystin, while the ratio of 
DsRed-positive cells in pDsRed transfection were not affected despite the 
presence of lactacystin.  Furthermore, immunoblot analysis confirmed that 
the DsRed-Cyclin I protein level increased by the inhibition of proteasome 
(Fig. 2B), suggesting that Cyclin I is degraded via the proteasome pathway. 
  To determine whether Cyclin I is ubiquitinated, Flag-tagged Cyclin I was 
transiently overexpressed in HEK293T cells together with HA-tagged 
ubiquitin (Fig. 2C).  After immunoprecipitation of Flag-Cyclin I, 
ubiquitinated Cyclin I was detected with anti-HA antibodies at high 
molecular weight regions when coexpressed with HA-ubiquitin, suggesting 
that Cyclin I is ubiquitinated in cells.  To further investigate the 
involvement of the PEST-rich region on Cyclin I ubiquitination, I generated a 
PEST motif deletion mutant (Cyclin I-PEST; amino acids 1 to 279).  When 
immunoprecipitated, ubiquitinated Cyclin I-PEST was also detected in the 
presence of HA-ubiquitin (Fig. 2C).  Although the level of ubiquitinated 
Cyclin I-PEST appeared to be higher than that of ubiquitinated Cyclin I-Wt, 
given that Cyclin I-PEST was more efficiently immunoprecipitated than 
Cyclin I-Wt, the ratio of the ubiquitinated form to the unmodified form was 
unchanged between Cyclin I-Wt and Cyclin I-PEST.  These results 
suggested that PEST-deleted Cyclin I is ubiquitinated similarly to full-length 
Cyclin I and that the PEST-rich region is not involved in the degradation of 
Cyclin I. 
 
Cyclin I associates with Cdk5 in vivo. 
  Next I tested whether an in vivo association between Cyclin I and Cdk5 
could be detected by coimmunoprecipitation (Fig. 3).  Flag-Cyclin I was 
transiently overexpressed in HEK293T cells together with HA-tagged Cdk5.  
After immunoprecipitation of Flag-Cyclin I, coprecipitated HA-Cdk5 was 
detected with anti-HA antibody (Fig. 3A).  Additionally, Flag-Cyclin I was 
also coprecipitated with HA-Cdk5 (Fig. 3B).  These results suggested that 
Cyclin I interacts with Cdk5 in vivo.  To confirm whether Cyclin I is 
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colocalized with Cdk5 in cells, HeLa cells transiently overexpressed with 
Flag-Cyclin I and HA-Cdk5 were stained with anti-Cyclin I and anti-HA 
antibodies (Fig. 3C).  Both of Cyclin I and Cdk5 were distributed 
throughout the cell, with a weak tendency for the enhanced signal of Cyclin I 
to be observed in the cytoplasm.  Although both of Cyclin I and Cdk5 were 
detected throughout the cell, the signals of Cyclin I and Cdk5 were not 
completely overlapping even though both proteins expressed in the same cell.  
These data suggested that Cyclin I can function in part mediated through 
complex formation with Cdk5. 
 
Knockdown of Cyclin I inhibits cell cycle progression. 
  To investigate the role of Cyclin I in cell cycle progression, I used siRNAs 
to deplete Cyclin I (Fig. 4).  HeLa cells were transfected with siRNAs for 
Cyclin I (Si_1, Si_3, Si_4, and Si_5) twice.  Two days after the second 
transfection of siRNAs, the level of Cyclin I was decreased, whereas the level 
of -tubulin was unaffected (Fig. 4A).  Because Cyclin I decreased 
particularly in cells transfected with Si_4 or Si_5, these siRNAs were used in 
subsequent experiments.  Proliferation of cells transfected with siRNAs was 
monitored by WST-1 assay (Fig. 4B).  Knockdown of Cyclin I effectively 
prevented cell proliferation, suggesting that Cyclin I contributes to cell 
proliferation.  To further confirm the effects of Cyclin I knockdown in cell 
cycle progression, cell cycle profiles were determined by flow cytometry (Fig. 
4C).  When Cyclin I was depleted, cells at G2/M phases slightly increased 
accompanying a decrease of cells at G1 phase, suggesting that Cyclin I plays 
the role in cell cycle progression around G2/M phases. 
  To confirm this, I used HeLa.S-Fucci (fluorescent ubiquitination-based cell 
cycle indicator) cells, which express monomeric Kusabira-Orange 2 (mKO2) 
and monomeric Azami-Green 1 (mAG1) fused to the ubiquitination domains 
of Cdt1 and geminin, respectively,13 to monitor cell cycle progression in situ.  
As Cdt1 and geminin are the direct substrates of SCFSkp2 and APC/CCdh1 
complexes, respectively, the level of Cdt1 is highest at the G1 phase whereas 
geminin is prominent during S, G2, and M phases.19  Therefore, the cell 
nuclei of HeLa.S-Fucci cells during the cell cycle are labeled with orange of 
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mKO2 fused to the ubiquitination domain of Cdt1 in G1 phase and green of 
mAG1 fused to the ubiquitination domain of geminin in S, G2, and M phases.  
In HeLa.S-Fucci cells, siRNA-mediated knockdown of Cyclin I was confirmed 
by immunoblot analysis (Fig. 5A).  Two days after transfection of siRNAs for 
Cyclin I, I observed HeLa.S-Fucci cells with fluorescent microscope (Fig. 5B).  
Total cell number of Cyclin I siRNAs-transfected cells seemed to decrease as 
compared with control siRNA-transfected cells, consistent with the result of 
Fig. 4B.  Cells transfected with siRNAs were counted and classified into 
each cell cycle phase according to the criteria as shown in Fig. 5C.  Cells 
depleted of Cyclin I were significantly accumulated at S/G2/M phases 
accompanying the decrease of G1 phase (Fig. 5D), confirming the result of 
flow cytometric analysis as shown in Fig. 4C.  These data strongly support 
the possibility that Cyclin I is involved in the cell cycle regulation at S and 
G2/M phases. 
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Discussion 
 
  In contrast to other cyclins, the Cyclin I mRNA level does not fluctuate 
during cell cycle progression,4-6 and therefore it has been believed that Cyclin 
I has no role in the regulation of cell proliferation.  However, I showed that 
Cyclin I expression was regulated during the cell cycle at the protein level 
and that depletion of Cyclin I prevented cell proliferation through the cell 
cycle arrest at S and G2/M phases. 
  Although Cyclin I contains the C-terminal PEST-rich region4 known as the 
destabilization domain,16 given that PEST motif-deleted Cyclin I was still 
ubiquitinated (Fig. 2C), Cyclin I is degraded by the ubiquitin-proteasome 
pathway presumably mediated through the region(s) other than the 
PEST-rich region.  Cyclin I shows the highest sequence similarity to Cyclins 
G1 and G2, and these two cyclins are also subjected to ubiquitination and 
degradation.20, 21  Furthermore, the cyclin box of Cyclin G1 plays a role in 
its degradation, suggesting that the functional interaction with Cdk can 
regulate the stability of Cyclin G1.  Therefore, it is possible that 
ubiquitination of Cyclin I is regulated by its interaction with Cdks or other 
proteins.  The elevation of Cyclin I protein in several tumors was reported.9, 
10, 22  As the ubiquitin-proteasome pathway is essential for the cell cycle 
regulation and cell proliferation, and dysregulation of this system leads to 
abnormal cell proliferation and tumor formation,18 the upregulated Cyclin I 
protein in tumor cells may be caused by the deregulated ubiquitin-mediated 
protein degradation system.   
  It has been suggested that Cdk5, the possible binding partner of Cyclin I, 
plays the role in many neuronal functions, such as differentiation, migration, 
and cell death.7, 8  As the activity of Cdk5 was mainly detected in 
postmitotic neurons, it has been considered that Cdk5 is not involved in cell 
cycle regulation.  Recently, the relationship between Cdk5 and cell cycle has 
been suggested by several studies.23-25  Futatsugi et al. have reported that 
nuclear translocated Cdk5 phosphorylates Rb to release E2F transcription 
factor, thereby inducing cell cycle re-entry of postmitotic neurons leading to 
apoptotic cell death,23 whereas Zhang et al. have shown that nuclear Cdk5 
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associates with E2F1 to inhibit dimer formation with DP1, the E2F1 cofactor, 
and suppresses cell cycle entry in neurons.24, 25  I observed that both Cyclin 
I and Cdk5 were detected throughout the cells (Fig. 3C).  Cytoplasmic Cdk5 
in proliferating cells may have different role from nuclear Cdk5.  Although 
the invovlement of Cdk5 in cell proliferation has not been suggested, it is 
possible that Cyclin I contributes to cell cycle regulation through activation 
of Cdk5.  However, this is still an open question because I have not detected 
the association of endogenous Cyclin I with Cdk5 yet.  Further studies are 
needed to evaluate the contribution of Cyclin I to cell proliferation mediated 
through Cdk5. 
  The reciprocal functions of Cyclin I have been suggested.  One is the 
contribution of Cyclin I to cell survival in post-differentiated and quiescent 
cells by activating Cdk5.6  The other one is the possible involvement of 
Cyclin I in proliferation of cancer cells.9, 10  The increased level of Cyclin I 
protein was observed in breast, ovarian, and pancreatic cancer cells.9, 10, 22  
Although the contribution of Cyclin I to cancer formation associated with 
angiogenesis was suggested,9, 10 the precise mechanisms were unknown.  In 
the present study, I showed the direct contribution of Cyclin I to cell 
proliferation by using siRNAs (Fig. 4).  Furthermore, cells depleted of 
Cyclin I were accumulated at S and G2/M phases (Fig. 4C and Fig. 5).  As 
cell cycle checkpoint operates to determine mitotic entry by monitoring DNA 
replication,26, 27 the results showing the upregulation of Cyclin I during S 
phase (Fig. 1) may suggest the involvement of Cyclin I in the regulation of 
DNA replication.  However, since the detailed molecular mechanisms by 
which Cyclin I regulates cell proliferation are still unknown, further 
investigation will be needed to clarify the role of Cyclin I in the regulation of 
the cell cycle.   
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Figures 
 
Fig. 1.  The protein level of Cyclin I oscillates during the cell cycle. 
 
Fig. 2.  Cyclin I is degraded via the ubiquitin-proteasome pathway. 
 
Fig. 3.  Cyclin I associates with Cdk5 in vivo. 
 
Fig. 4.  Knockdown of Cyclin I inhibits cell cycle progression in HeLa cells. 
 
Fig. 5.  Knockdown of Cyclin I inhibits cell cycle progression in 
HeLa.S-Fucci cells. 
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Fig. 1.  The protein level of Cyclin I oscillates during the cell cycle.  HeLa 
cells were arrested at late G1 phase with the double-thymidine block, 
followed by the release to enter S phase.  Lysates from cells at each time 
point were subjected to SDS-PAGE, followed by immunoblotting with 
antibodies as indicated.  Cyclin E and Cyclin B1 were used for the cell cycle 
markers of G1/S and G2/M phases, respectively. 
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Fig. 2.  Cyclin I is degraded via the ubiquitin-proteasome pathway.  (A and 
B) Increasing level of Cyclin I by proteasome inhibition.  HEK293T cells 
were transfected with pDsRed-Cyclin I.  After incubation for 16 h, cells 
were treated with or without 10 g/ml lactacystin for 24 h.  Cells were 
observed with fluorescence microscope (A) or the lysates were fractionated by 
SDS-PAGE and immunoblotted with antibodies as indicated (B).  Bars, 50 
m.  (C) Ubiquitination of Cyclin I.  HEK293T cells were transfected with 
pTB701-Flag-Cyclin I-Wt, pTB701-Flag-Cyclin I-PEST, and 
pCGN-HA-ubiquitin as indicated.  After incubation for 24 h, cells were 
treated with 10 g/ml lactacystin for 6 h, and the lysates were 
 21 
immunoprecipitated with anti-Flag M2 agarose beads.  The input lysates 
and the immunoprecipitates were fractionated by SDS-PAGE and 
immunoblotted with antibodies as indicated. 
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Fig. 3.  Cyclin I associates with Cdk5 in vivo.  (A and B) Coprecipitation of 
Cyclin I with Cdk5 in transiently overexpressed HEK293T cells.  Lysates 
from HEK293T cells transfected with pTB701-Flag-Cyclin I and 
pcDNA3-HA-Cdk5 were immunoprecipitated with anti-Flag agarose beads 
(A) or anti-HA antibody (B).  The input lysates and the immunoprecipitates 
were fractionated by SDS-PAGE and immunoblotted with antibodies as 
indicated.  (C) Colocalization of Cyclin I and Cdk5 in transiently 
overexpressed HeLa cells.  HeLa cells were transfected with 
pTB701-Flag-Cyclin I and pcDNA3-HA-Cdk5.  After fixation and 
permeabilization, cells were incubated with anti-Cyclin I antibody and 
anti-HA antibody, followed by staining nuclei with Hoechst 33258.  Bars, 10 
m. 
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Fig. 4.  Knockdown of Cyclin I inhibits cell cycle progression in HeLa cells.  
(A) Knockdown of Cyclin I in HeLa cells.  HeLa cells were transfected with 
siRNAs for negative control (Control) or Cyclin I (Si_1, Si_3, Si_4, and Si_5) 
at day 0 and day 1, and then the expression level of Cyclin I was determined 
by immunoblot analysis at day 3.  The protein level relative to the -tubulin 
level was quantified using NIH ImageJ software.  (B) The proliferation 
rates of Cyclin I-depleted HeLa cells.  HeLa cells were cultured as described 
in (A), and cell proliferation was assessed by WST-1 assay at days 1, 2, and 3.  
(C) Cell cycle profiles of Cyclin I-depleted HeLa cells.  HeLa cells were 
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cultured as described in (A), and cell cycle profiles were determined by flow 
cytometry at day 3.  Representative flow cytometric data are depicted (left), 
and the bar graph and the table show quantification of flow cytometric 
analysis (right).  Each value represents the mean ± SD of three 
independent experiments.  Statistical significance is shown using the 
Student’s t-test analysis; *P < 0.05; **P < 0.01; ***P < 0.001. 
 25 
 
 
 
Fig. 5.  Knockdown of Cyclin I inhibits cell cycle progression in 
HeLa.S-Fucci cells.  (A) Knockdown of Cyclin I in HeLa.S-Fucci cells.  
HeLa.S-Fucci cells were transfected with siRNAs for negative control 
(Control) or Cyclin I (Si_4, and Si_5) at day 0 and day 1, and then the 
expression level of Cyclin I was determined by immunoblot analysis at day 3.  
The protein level relative to the -tubulin level was quantified using NIH 
ImageJ software.  (B) Fluorescence microscopy images of Cyclin I-depleted 
HeLa.S-Fucci cells.  HeLa.S-Fucci cells were cultured as described in (A), 
and then observed with fluorescence microscope at day 3.  The morphology 
of cells and the color of cell nuclei were shown by phase contrast, mKO2, 
mAG1, and merged images, respectively.  Bars, 50 m.  (C) The criteria for 
the classification of HeLa.S-Fucci cells into each cell cycle phase.  Cells with 
mKO2 were at G1 phase, cells with both mKO2 and mAG1 were at the 
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border of G1 and S phases, cells with mAG1 were at S, G2, and M phases, 
and cells with neither mKO2 nor mAG1 were at the transition from M to G1 
phases as described previously.28  (D) The ratio of cell cycle phase of Cyclin 
I-depleted cells.  HeLa.S-Fucci cells were cultured as described in (A).  
Cells were counted and classified into each cell cycle phase according to the 
criteria as shown in (C).  Each value represents the mean ± SD of four 
counts of at least 120 cells.  Statistical significance is shown using the 
Student’s t-test analysis; *P < 0.05; **P < 0.01. 
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Chapter II 
 
Identification and functional characterization of proline 
dehydrogenase (PRODH) as an inducer of senescence  
 
 
 
Abstract 
 
  Cellular senescence is defined as permanent cell cycle arrest induced by 
various stresses.  Although the p53 transcriptional activity is essential for 
senescence induction, the downstream genes that are crucial for senescence 
remain unsolved.  Here, by using a developed experimental system in which 
cellular senescence or apoptosis is induced preferentially by altering 
concentration of etoposide, a DNA-damaging drug, I compared gene 
expression profiles of senescent and apoptotic cells by microarray analysis.  
Subtraction of the expression profile of apoptotic cells identified 20 genes 
upregulated specifically in senescent cells.  Among these genes, proline 
dehydrogenase (PRODH) and D-amino acid oxidase (DAO) were directly 
regulated by p53, and PRODH induced senescence via generation of reactive 
oxygen species (ROS) and the following enhancement of DNA damage.  
Genetic and pharmacologic inhibition of PRODH suppressed senescence 
induced by DNA damage.  These results implicate PRODH upregulation by 
p53 as a critical step in DNA damage-induced senescence. 
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Abbreviations 
 
Act D: Actinomycin D 
cDNA: complementary DNA 
ChIP: chromatin immunoprecipitation 
DDR: DNA damage response 
DMSO: dimethyl sulfoxide 
FBS: fetal bovine serum 
HA: hemagglutinin 
L-THFA: L-tetrahydro-2-furoic acid 
NAC: N-acetyl-L-cysteine 
PARP: poly(ADP-ribose) polymerase 
PI: propidium iodide 
pPCR: quantitative PCR 
ROS: reactive oxygen species 
SA--Gal: senescence-associated -galactosidase 
SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
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Introduction 
 
  Cellular senescence was first described as a process of irreversible cell 
cycle arrest resulting from the limited replicative capacity of human diploid 
fibroblasts in culture.1  Although this process, now termed as replicative 
senescence, is associated with telomere shortening,2 senescence can be also 
induced independent of telomere erosion as a consequence of various forms of 
stress, such as activated oncogenes, ROS, and DNA damage,3-5 and is 
referred to as premature senescence.  It has been suggested that DNA 
damage is a common mediator for various forms of senescence induced by 
diverse stimuli including telomere shortening.6-9  In response to DNA 
damage, the DNA damage response (DDR) is initiated by 
phosphatidylinositol 3-kinase like kinases such as ATM and ATR.  Once 
activated, ATM and ATR phosphorylate downstream checkpoint kinases 
Chk1 and Chk2, which in turn phosphorylate and activate p53 to affect cell 
cycle progression.  The p53 tumor suppressor protein is a critical 
transcription factor that regulates cell proliferation and death.10  Besides 
inducing senescence, activated p53 also modulates transient cell cycle arrest 
and apoptosis to act as a genome guardian.  These cellular responses 
depend on the expression of respective sets of particular p53 target genes.11, 
12 
  Microarray-based gene expression profiling is frequently used to identify 
targets of transcription factors, and the list of p53 downstream effectors that 
mediate tumor suppressor function of p53 through induction of transient cell 
cycle arrest, senescence, and apoptosis is sizable.12-14  However, the gene 
expression analyses concerning the different modes of p53 activation have 
identified overlapping sets of downstream p53 targets, and the p53 
transcriptional targets required specifically for initiation and maintenance of 
senescence phenotypes have not been fully elucidated.15, 16  Although the 
Cdk inhibitor p21, a target of p53, has been considered as central to arrest 
cell cycle in senescent cells,17-19 it is questioned whether expression of p21 is 
necessary and sufficient for senescence induction.20-22  
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  In the present study, I developed an experimental system in which either 
senescence or apoptosis is specifically induced in the same cell line by 
altering dosage of a DNA-damaging drug and compared gene expression 
profiles by using microarray analysis in an attempt to distinguish genes 
specific for senescence from those that universally respond to DNA damage.  
After comparison of the expression profiles between senescent and apoptotic 
cells, 20 genes were identified being upregulated in p53-dependent 
senescence.  Furthermore, I validated PRODH and DAO as direct 
transcriptional targets of p53 and provided evidence that PRODH induces 
senescence by generating ROS and enhancing DNA damage. 
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Materials and Methods 
 
Cell culture, treatment, and transfection. 
  HepG2 (a human hepatocellular carcinoma line; a gift from Dr. S. Shimizu) 
cells were cultured in RPMI 1640 medium (Wako) supplemented with 10% 
fetal bovine serum (FBS).  U2OS (a human osteosarcoma line; ATCC), 
SaOS-2 (a human osteosarcoma line; a gift from Dr. M. Takahashi), and 
Hs68 (normal human diploid fibroblasts; Japanese Collection of Research 
Bioresources Cell Bank) cells were cultured in DMEM (Wako) supplemented 
with 10% FBS.  The cells were treated with etoposide (Sigma Aldrich) or 
bleomycin (Wako) to induce DNA double-strand breaks.  For senescence 
induction, HepG2 cells were treated with 10 M etoposide for 48 h and used 
for subsequent assays, while U2OS cells were treated with 2 or 5 M 
etoposide or 2 M bleomycin for 48 h and cultured in the medium without 
the drugs for additional 5 days to develop senescent phenotypes.  CGK733 
(Calbiochem) or KU-55933 (Calbiochem) was added to the medium 1 h before 
etoposide treatment.  Inhibition of transcription was achieved by incubating 
the cells with 50 ng/ml Actinomycin D (Act D; Sigma Aldrich).  When 
N-acetyl-L-Cysteine (NAC; Sigma Aldrich) was employed, the cells were 
incubated with the reagent at 5 mM.  To inhibit PRODH, the cells were 
incubated with 5 mM L-tetrahydro-2-furoic acid (L-THFA; Sigma Aldrich).  
Stock solutions of etoposide, CGK733, KU-55933, and Act D were prepared 
in dimethyl sulfoxide (DMSO), while bleomycin, NAC, and L-THFA were 
dissolved in water.  Transfection with expression vectors was performed 
using FuGENE HD (Promega) according to the manufacturer’s instruction.  
The transfectants were selected with 800 g/ml G418 (Wako) for 5 days. 
 
Senescence assays. 
  For colony formation assay, 1000, 5000, or 10000 cells were plated in 
35-mm dish, cultured for 7-10 days, and stained with crystal violet (Wako).  
Detection of senescence-associated -galactosidase (SA--Gal) activity was 
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performed using Senescence -Galactosidase staining kit (Cell Signaling 
Technology) according to the manufacturer’s instruction.  Briefly, the cells 
were fixed with 2% formaldehyde/0.2% glutaraldehyde for 15 min, and 
washed twice with phosphate-buffered saline.  After incubation with 
SA--Gal staining solution (1 mg/ml 5- 
bromo-4-chloro-3-indolyl--D-galactoside, 40 mM citric acid/sodium 
phosphate [pH 6.0], 5 mM potassium ferrocyanide, 5 mM potassium 
ferricyanide, 150 mM NaCl, 2 mM MgCl2) for 12 h (HepG2 cells) or 24 h 
(U2OS cells), the cells were examined under fluorescence microscope (model 
BZ-8000; Keyence).  Senescent cells were identified as blue-stained cells 
with phase contrast, and at least 100 cells were counted to determine the 
percentage of SA--Gal positive cells. 
 
Apoptosis assay. 
  The Annexin-V-FLUOS Staining Kit (Roche) was used to detect apoptotic 
cells according to the manufacturer’s instruction.  The cells were harvested 
and resuspended in Annexin-V-FLUOS buffer containing propidium iodide.  
After 20 min of incubation, the stained cells were analyzed by flow cytometry 
(FACSCalibur; Becton-Dickinson) or observed under fluorescence 
microscope. 
 
Antibodies. 
  Anti-Caspase-3 antibody (#9662), anti-PARP antibody (#9542), 
anti-phospho-Chk1 (Ser296) antibody (#2349), anti-phospho-Chk1 (Ser317) 
antibody (#2344), anti-phospho-Chk1 (Ser345) antibody (#2348), anti-Chk1 
antibody (#2345), anti-phospho-Chk2 (Thr68) antibody (#2661), 
anti-phospho-Chk2 (Ser516) antibody (#2669), anti-Chk2 antibody (#2662), 
anti-phospho-p53 (Ser15) antibody (#9284), and anti-phospho-p53 (Ser20) 
antibody (#9287) were obtained from Cell Signaling Technology; anti-p53 
antibody (DO-1; sc-126), anti-PRODH antibody (sc-376401), and 
HRP-conjugated anti-rat antibody (sc-2032) were from Santa Cruz 
Biotechnology; anti--tubulin antibody (T9026) and anti--tubulin antibody 
(T6557) were from Sigma Aldrich; anti-p21 antibody (K0081-3) and 
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anti-ATM antibody (PM026) were from Medical and Biological Laboratories; 
HRP-conjugated anti-rabbit antibody (W4011) and HRP-conjugated 
anti-mouse antibody (W4021) were from Promega; anti-HA antibody 
(1867423) was from Roche; anti-DAO antibody (6844-1) was from Abcam; 
anti-H2AX antibody (05-636) was from Millipore. 
 
Immunoblot analysis. 
  The cells were lysed in lysis buffer (1% Nonidet P-40, 50 mM Tris-HCl [pH 
7.5], 5 mM EDTA, 150 mM NaCl, 20 mM NaF, 20 mM -glycerophosphate, 10 
g/ml leupeptin, 10 g/ml aprotinin, 1 mM phenylmethanesulfonyl fluoride).  
The lysates were separated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) and blotted onto Immobilon polyvinylidene difluoride 
membrane (Millipore).  Each protein was detected using primary antibodies 
as indicated, HRP-conjugated secondary antibodies, and the ECL detection 
reagent (GE Healthcare).  Phos-tag SDS-PAGE was performed with 
polyacrylamide gels containing 100 M Phos-tag (Wako) and 200 M MnCl2. 
 
RNA interference. 
  siRNAs for ATM (ATM_1: Hs_ATM_8 SI00604730, ATM_2: Hs_ATM_12 
SI02663360, ATM_3: Hs_ATM_5 SI00299299, and ATM_4: Hs_ATM_9 
SI00604737), Chk1 (Chk1_1: Hs_CHEK1_8 SI00605094, Chk1_2: 
Hs_CHEK1_9 SI00287658, Chk1_3: Hs_CHEK1_7 SI00299859, and Chk1_4: 
Hs_CHEK1_13 SI02660007), p53 (p53_1: Hs_TP53_3 SI00011655, p53_2: 
Hs_TP53_7 SI02623747, p53_3: Hs_TP53_9 SI02655170, and p53_4: 
Hs_TP53_13 SI04384079), and control siRNA (SI03650318) were obtained 
from Qiagen.  ON-TARGETplus Smart Pool siRNA for PRODH 
(L-009543-00) and its control siRNA (D-001810-10) were from Thermo 
Scientific Dharmacon.  HepG2 or U2OS cells were seeded and transfected 
with 30 nM siRNAs using HiPerFect Transfection Reagent (Qiagen) 
according to the manufacturer’s instruction. 
 
Plasmid constructions. 
  The cDNA corresponding to the amino acid sequence of human Chk1 
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(NCBI accession number NP_001107594.1) was purchased from Kazusa 
DNA Research Institute and cloned into downstream of the Flag tag 
sequence in the pcDNA3-Flag vector (Invitrogen) to generate 
pcDNA3-Flag-Chk1.  The cDNA fragments of human PVRL4 (NP_112178.2), 
PRODH (NP_057419.4), LY6D (NP_003686.1), DAO (NP_001908.3), and 
EPN3 (NP_060427.2) were amplified from a cDNA sample prepared from 
U2OS cells.  The cDNA fragment of human GPR172B (NP_001098047.1) 
was amplified from a plasmid containing PAR2 cDNA (kindly provided by Dr. 
Y. Takeuchi).  The resultant fragments were digested with appropriate 
restriction enzymes and cloned into downstream of the hemagglutinin (HA) 
tag sequence in the pcDNA3-HA vector.  To generate mutants of Chk1 
(S345A) and PRODH (L441P and R453C), PCR reactions were performed 
using mutagenic primers.  The sequences of primers used for plasmid 
constructions are listed in Table 1. 
 
RNA isolation and microarray analysis. 
  RNA was isolated using NucleoSpin RNA II (TaKaRa) according to the 
manufacturer’s instruction.  The quantity and purity of the extracted RNA 
were evaluated using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific).  Expression profiling was performed by DNA Chip Research, Inc. 
using Whole Human Genome DNA Microarray 4 x 44 K (Agilent 
Technologies). 
 
Quantitative PCR (qPCR). 
  Total RNA was isolated from the cells as described above.  cDNAs were 
generated from 500 ng of isolated RNA using ReverTra Ace qPCR RT Master 
Mix with gDNA Remover (TOYOBO).  qPCR was performed using 
THUNDERBIRD SYBR qPCR Mix (TOYOBO) with the LightCycler480 
Real-Time PCR System (Roche Applied Science).  Primer sequences for 
qPCR are listed in Table 1.  Relative expression levels were quantified by 
constructing a standard curve using serial dilutions of the cDNA samples.  
GAPDH was served as endogenous normalization control. 
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Chromatin immunoprecipitation (ChIP). 
  ChIP assay was performed using the EZ Magna ChIP kit (Millipore).  Ten 
million cells were used per each ChIP experiment.  The cells were 
cross-linked with 1% formaldehyde and subsequently treated with 125 mM 
glycine, and then lysed and sonicated with a Bioruptor UCD-300 (Cosmo Bio) 
for 4 min at high power.  Antibody incubation with chromatin was 
performed overnight at 4°C with 1 g of p53 antibody (DO-1) or normal 
mouse IgG.  Antibody-chromatin complexes were washed four times with 
Wash Buffers and eluted with ChIP Elution Buffer.  Cross-links were 
reversed by incubation at 95°C for 10 min, and DNA was purified with Spin 
column.  Purified DNA was quantified by qPCR as described above.  The 
JASPAR database (http://jaspar.binf.ku.dk) was used to search for putative 
p53 response elements.  Primer sequences are listed in Table 1. 
 
ROS assay. 
  ROS levels were determined by using the ROS-Glo H2O2 Assay kit 
(Promega) following the manufacturer’s protocol.  In brief, the cells were 
incubated at 37°C for 3 h in DMEM containing 25 M H2O2 Substrate that 
reacts with H2O2 to generate a luciferin precursor.  Afterwards, ROS-Glo 
Detection Solution containing recombinant luciferase was added to the 
medium, and luminescence was measured using a Mithras LB940 
luminometer (Berthold). 
 
Immunofluorescence. 
  For immunofluorescence analysis, the cells were fixed with 4% 
paraformaldehyde, permeabilized in 0.5% TritonX-100, and then incubated 
with primary antibodies in Can Get Signal immunostain Solution B 
(TOYOBO) overnight at 4°C followed by incubation with Alexa Fluor 488- or 
Alexa Fluor 546-conjugated secondary antibody (Molecular Probes) for 1 h at 
room temperature.  After staining cell nuclei with Hoechst 33258, the cells 
were examined under fluorescence microscope.  For mitochondria staining, 
the cells were incubated with 250 nM MitoTracker Red CMXRos (Life 
Technologies) for 30 min prior to fixation. 
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Results 
 
Senescence is induced by the low dose of etoposide, whereas apoptosis is 
triggered at higher doses. 
  Although etoposide, an anticancer drug that causes DNA double-strand 
breaks, has been reported to induce both senescence and apoptosis,23, 24 it 
remains unclear what molecules contribute to the induction of senescence or 
apoptosis by etoposide.  Here, I investigated the phenotypes of two human 
tumor lines expressing the wild-type p53, hepatocarcinoma HepG2 cells and 
osteosarcoma U2OS cells, as a function of the dosage of etoposide. 
  After treatment of HepG2 cells with a relatively lower dose of etoposide (10 
M), I observed the cells showing the arrest of proliferation and the 
enlargement of cell morphology, which are the typical features of senescent 
cells (Fig. 1A).  In contrast, treatment with a higher dose of etoposide (50 
M) caused cell shrinkage, which represents the morphological sign of 
apoptosis.  To evaluate the extent of senescence and apoptosis induced by 
different doses of etoposide, cells treated with etoposide at 10, 50, and 
100M were examined for the markers of senescence and apoptosis.  At the 
low dose (10 M), etoposide-treated cells showed loss of the colony-forming 
ability (Fig. 1B), and the activity of SA--Gal, a well-known senescence 
marker,25 gradually increased in a time-dependent manner (Fig. 1, C and D).  
To assess apoptosis, cells treated with a range of etoposide doses were 
stained with Annexin V, as a marker of apoptosis (Fig. 1E).  Approximately 
10% of apoptotic cells were observed in cultures treated with the low dose of 
etoposide for 48 h, whereas about 30 and 40% of apoptotic cells were 
measured in cultures exposed to 50 and 100 M etoposide, respectively.  
Consistent with this, immunoblot analysis revealed that cleavage of 
caspase-3 and poly(ADP-ribose) polymerase (PARP), a substrate for caspases, 
was detected at high etoposide doses (50 and 100 M) but not at the low dose 
(10 M) (Fig. 2).  These results suggest that etoposide at the low dose 
mainly induces senescence, whereas it causes primarily apoptosis at high 
doses in HepG2 cells. 
  To confirm these results, U2OS cells were treated with different doses of 
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etoposide and bleomycin, another DNA damage-inducing drug that has a 
different mode of action from etoposide to induce DNA double-strand 
breaks.26  Consistent with the findings in HepG2 cells, a low dose (2 M) of 
etoposide and bleomycin reduced the colony-forming ability of U2OS cells 
(Fig. 3A) and increased the number of SA--Gal-positive cells in a 
time-dependent manner (Fig. 3B).  In addition, apoptosis occurred at the 
high dose of etoposide (100 M) but not at low doses (2 and 5 M) as 
evidenced by propidium iodide (PI) staining and PARP cleavage (Fig. 3, C 
and D).  These results indicate that senescence is also induced mainly by 
low doses of the drugs, and apoptosis predominates at the high dose in U2OS 
cells. 
 
p53 transcriptional activation between 24 h and 36 h after treatment with 
the low dose of etoposide is required for senescence induction 
  As senescence is mediated through the activation of checkpoint kinases 
involved in the DDR,6-9 I examined the relationship between DDR signaling 
and etoposide-induced senescence.  The DDR is composed of DNA damage 
sensing, amplification of activities of upstream kinases ATM and ATR, the 
signal transduction through downstream kinases Chk1 and Chk2, and 
effector protein p53.  Consistently, treatment of HepG2 cells with CGK733, 
an ATM/ATR inhibitor, and KU-55933, an ATM inhibitor, effectively 
prevented senescence induced by etoposide (Fig. 4, A and B).  Similar 
results were obtained when ATM was depleted by siRNAs (Fig. 4C).  
Moreover, depletion of Chk1 also suppressed etoposide-induced senescence 
(Fig. 4D). 
  To further obtain information on DDR kinases responsible for senescence 
and apoptosis induced by etoposide, I assessed the phosphorylation states of 
Chk1 and Chk2 (Fig. 2).  ATM and ATR phosphorylate Chk1 at Ser317 and 
Ser345, which induces functionally essential autophosphorylation at 
Ser296.27, 28  The phosphorylation levels of Chk1 at Ser296, Ser317, and 
Ser345 increased and remained high even after 24 h treatment with the low 
dose of etoposide, whereas at high doses, Chk1 phosphorylation increased 
during first 12 h but decreased immediately 24 h after treatment, raising the 
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possibility that a relatively prolonged activation of Chk1 could lead the cells 
to senescence.  ATM and ATR also phosphorylate Chk2 at Thr 68, which 
promotes dimerization of Chk2 and autophosphorylation at Thr383, Thr387, 
and Ser516.27, 29  In contrast to Chk1, the phosphorylation levels of Chk2 at 
Thr68 and Ser516 similarly increased in response to etoposide at both low 
and high doses.  To confirm the response of Chk1 phosphorylation to the 
different doses of etoposide, I applied U2OS cells for the analysis (Fig. 3D).  
The phosphorylation of Chk1 at Ser345 gradually increased until 48 h after 
treatment with the low dose of etoposide, while at the high dose, Chk1 
phosphorylation sharply reduced 36 h after treatment.  Moreover, although 
ectopic expression of wild-type Chk1 promoted etoposide-induced senescence, 
no such effect was observed by overexpressing Chk1 mutant S345A (Ser345 
was substituted with alanine) (Fig. 4E).  These results suggest that the 
prolonged Chk1 activation after treatment with the low dose of etoposide 
may be necessary for the induction of senescence. 
  Since Chk1 activates p53 by phosphorylation, and p53 is a critical factor 
for senescence induction, I analyzed the phosphorylation states of p53 (Fig. 
2).  The phosphorylation of p53 occurs at several sites, such as at Ser15 and 
Ser20, and these phosphorylation events are important for p53 stabilization.  
The phosphorylation levels of p53 at Ser20 dramatically increased until 24 h 
after treatment with the low dose of etoposide accompanying the increase of 
p53 protein, and sustained for up to 48 h, which is consistent with the 
prolonged activation of Chk1 (Fig. 2).  However, high doses of etoposide did 
not cause the increase of Ser20 phosphorylation or the protein level of p53 
during the period of 24-48 h.  Meanwhile, p53 phosphorylation at Ser15 
increased similarly at both low and high doses throughout the time course of 
treatment.  These results suggest that p53 activation through the 
phosphorylation at particular site(s) between 24 and 48 h after etoposide 
treatment may be needed to induce senescence. 
  To test whether etoposide-induced senescence is dependent on p53, I used 
siRNAs to deplete p53.  As two siRNAs (p53_1 and p53_2) effectively 
decreased the protein levels of p53 and p21, a downstream target of p53, in 
the presence of etoposide, these siRNAs were used in subsequent 
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experiments (Fig. 5A).  Knockdown of p53 remarkably decreased 
etoposide-induced senescence, suggesting that senescence induced by the low 
dose of etoposide was highly dependent on p53 (Fig. 5A). 
  Next, to investigate whether senescence induction is dependent on p53 
transcriptional activity between 24 and 48 h after treatment with the low 
dose of etoposide and, if so, determine at what time point transcription is 
required, the transcriptional inhibitor, actinomycin D (Act D), was added to 
the culture medium at four different time points (24, 30, 36, and 42 h) after 
exposure to etoposide.  After 6 h of incubation in the presence of Act D and 
etoposide, the drugs were washed out by replacing the medium, and cells 
retreated only with etoposide up to for 48 h after initial etoposide exposure 
were subjected to SA--Gal staining (Fig. 5B).  When treated with Act D 
from 24 to 30 h (24-30 h) or 30-36 h after exposure to etoposide, senescence 
was completely blocked, whereas inhibition of transcription 36-42 h after 
etoposide exposure partially suppressed senescence, and the addition of Act 
D after 42 h had no significant effect.  Although Act D is a general 
transcriptional inhibitor, given that etoposide-induced senescence was 
highly dependent on p53, these results suggest that the transcriptional 
activation of p53-target genes between 24 h and 36 h after etoposide 
treatment is required for senescence induction. 
  Furthermore, I applied the Phos-tag SDS-PAGE method to compare the 
overall p53 phosphorylation patterns after 24 h treatment with low and high 
doses of etoposide.  The Phos-tag polymerized into the SDS-polyacrylamide 
gel binds to phosphate groups and enhances the phosphorylation-dependent 
mobility shift.30-32  Lysates from HepG2 cells treated with low and high 
doses of etoposide for 24 h were subjected to Phos-tag SDS-PAGE and 
immunoblotted with the anti-p53 antibody.  After treatment with etoposide, 
p53 was separated into several bands with large mobility differences, 
whereas no mobility shift was detected in the absence of etoposide (Fig. 5C).  
More importantly, the p53 banding patterns differed between low and high 
doses of etoposide.  At the low dose, stronger signals were observed in the 
relatively lower bands, while more intense bands appeared at higher region 
at the high dose, reflecting the different phosphorylation patterns of p53 
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between low and high etoposide doses.  Since some of the posttranslational 
modifications of p53, including phosphorylation, influence p53’s target gene 
selection,33 these results further support the idea that distinct sets of target 
genes are transcriptionally activated by p53 in response to different doses of 
etoposide. 
 
PRODH and DAO are upregulated at only low but not high doses of 
etoposide, and their upregulation is dependent on p53. 
  To identify downstream transcriptional targets differentially expressed in 
cells treated with different doses of etoposide, I profiled the transcriptome of 
HepG2 cells treated with low and high doses of etoposide for 30 h using 
microarray analysis.  Gene expression profiling revealed that 126 genes 
were upregulated more than 3-fold at the low dose of etoposide as compared 
with control cells.  In addition, when compared the expression profiles of 
these genes between low and high doses, 25 genes were found to be 
differentially upregulated by more than 2-fold at the low dose.  After 
exclusion of 3 genes with well-established function and 2 genes encoding 
hypothetical proteins, 20 genes were selected for further analysis (Table 2).  
Genes previously shown to be involved in senescence induction, such as 
E2F7, p21, BTG2, and SULF2,17, 18, 34-37 were identified to be upregulated in 
this screening, however, the expression of p21, BTG2, and SULF2 increased 
to a similar extent at low and high doses (<2-fold difference).  Microarray 
results were further confirmed by qPCR.  With the exception of 3 genes, 17 
out of 20 identified genes showed higher expression in cells treated with the 
low dose of etoposide compared with that at the high dose (Table 2).   
  To investigate whether the expression of the selected genes is dependent 
on p53, I compared U2OS and SaOS-2 cells, which have the wild-type p53 
and are deficient of p53, respectively.  qPCR analysis showed that 7 out of 
17 genes were upregulated by more than 2-fold in U2OS cells treated with 
etoposide and bleomycin (Table 3).  In contrast, such increases were absent 
or reduced in SaOS-2 cells with the exception of the IGFBP2 gene, 
suggesting that upregulation of 6 genes (PVRL4, PRODH, LY6D, DAO, 
EPN3, and GPR172B) upon etoposide treatment is dependent on p53.  To 
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confirm these results, the expression levels of these 6 genes were compared 
between p53 wild-type and p53-knockdown HepG2 cells.  Depletion of p53 
prevented the etoposide-induced upregulation of all 6 genes (Fig. 6A).  Next, 
I tried to determine whether p53 binds to the genomic regions of the 6 genes.  
By analyzing the sequences of these genes, I identified putative p53 response 
elements: in the promoters of PVRL4, LY6D, and EPN3; in the first intron of 
DAO; in the third intron of PRODH; in the fifth intron of GPR172B.  
Chromatin immunoprecipitation (ChIP) assay using the anti-p53 antibody in 
HepG2 cells treated with etoposide revealed that p53 bound to the genomic 
regions of PRODH and DAO when treated with etoposide (Fig. 6B).  
Furthermore, immunoblot analysis indicated that the protein levels of 
PRODH and DAO increased in response to etoposide, which were abolished 
by depletion of p53 (Fig. 6C).  Moreover, PRODH and DAO protein levels 
also increased in U2OS cells but not in SaOS-2 cells when treated with 
etoposide (Fig. 6D).  These results suggest that PRODH and DAO are 
directly regulated by p53 upon DNA damage. 
 
PRODH, DAO, and EPN3 promote senescence, whereas GPR172B inhibits 
senescence. 
  To test whether the 6 genes contribute to the senescence program, 
expression vectors containing these genes were introduced individually into 
U2OS cells.  Immunoblot analysis validated that each of the proteins was 
expressed in cells (Fig. 7A).  Ectopic expression of p21 (positive control), 
PRODH, LY6D, and EPN3 enhanced activity of SA--Gal regardless of 
whether or not etoposide was present (Fig. 7B).  Ectopic DAO increased 
SA--Gal activity of etoposide-treated cells, whereas the cells overexpressing 
GPR172B showed decreased SA--Gal activity in the presence of etoposide.  
Furthermore, ectopic expression of p21, PRODH, DAO, PVRL4, and EPN3 
decreased the colony-forming ability (Fig. 7C).  These results suggest that 
PRODH, DAO, and EPN3 can promote senescence, and that GPR172B may 
act to suppress senescence. 
  The expression levels of these 6 genes were also assessed in normal human 
diploid fibroblasts Hs68 cells triggered to undergo senescence by replicative 
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exhaustion (Fig. 8).  Induction of replicative senescence in aged Hs68 cells 
(at passages 58 and 65) was confirmed by SA--Gal staining (Fig. 8A).  The 
expression levels of all 6 genes were elevated during replicative senescence 
to various extents (Fig. 8B), suggesting that upregulation of these genes is a 
general phenomenon in senescence. 
 
PRODH induces senescence via ROS production and the following 
enhancement of DDR signaling 
  Among this set of genes, I focused on the relationship between PRODH 
and senescence induction for the following reasons:  (a) upregulation of 
PRODH in response to etoposide required the presence of functional p53 
(Table 3, and Fig. 6, A, C, and D), and ChIP assay demonstrated the direct 
interaction of p53 with PRODH (Fig. 6B), suggesting that PRODH is a direct 
transcriptional target of p53.  (b) Ectopic expression of PRODH promoted 
senescence as measured by SA--Gal staining and colony-formation assay 
(Fig. 7, B and C).  (c) PRODH is a mitochondrial inner 
membrane-associated protein catalyzing the first step in proline catabolism 
and is known to promote formation of mitochondrial ROS as a byproduct of 
the oxidation of proline.38  The increased accumulation of intracellular ROS 
in senescent cells has been widely reported.7-9, 39 
  First, I confirmed the importance of PRODH in etoposide-induced 
senescence by using siRNA for PRODH (Fig. 9, A and B).  Next, I examined 
whether the upregulation of PRODH results in ROS accumulation.  As 
shown in Fig. 9C, the ROS level was elevated in U2OS cells overexpressing 
PRODH compared with empty vector-transfected cells.  In addition, 
treatment with N-acetyl-L-Cysteine (NAC), a potent ROS scavenger, 
markedly suppressed SA--Gal activity induced by PRODH overexpression, 
while senescence induced by p21 was unaffected by NAC (Fig. 9D), 
suggesting that induction of senescence by ectopic PRODH expression 
occurred via the generation of ROS.  Next, the impact of inhibiting PRODH 
activity on senescence was tested using L-tetrahydro-2-furoic acid (L-THFA), 
previously identified and characterized for the ability to inhibit enzymatic 
activity of PRODH.40  The increase in ROS production upon etoposide 
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treatment was partially suppressed by co-treatment with L-THFA (Fig. 9E).  
In addition, I observed that L-THFA was highly effective in suppressing 
SA--Gal activity of cells treated with etoposide (Fig. 9F).  To further 
confirm that the effect of PRODH on senescence induction is due to its 
enzymatic activity, I generated two PRODH mutants with a point mutation 
(L441P and R453C), both of which were shown to have little enzymatic 
activity (<10% activity) in vitro,41 as confirmed by the inability to increase 
intracellular ROS levels in contrast to wild-type (Wt) PRODH (Fig. 9, G and 
H).  Unlike Wt-PRODH, both mutants were unable to promote senescence 
both in the absence and presence of etoposide as judged by SA--Gal staining 
(Fig. 9I). 
  ROS can cause DNA damage, and the DDR signaling is an important 
initiator and sustainer of the senescent state.  Given the role of PRODH in 
ROS production, I next tried to determine whether PRODH overexpression 
induces DNA damage.  For this purpose, I monitored DNA double-strand 
breaks using a well-established marker, phosphorylated histone H2AX 
(H2AX).  Upon DNA breakage, H2AX is phosphorylated by ATM, and foci 
of H2AX are formed at the double-strand break sites.42  Mitochondrial 
localization of HA-PRODH was confirmed using the mitochondria-specific 
fluorescent dye, MitoTracker (Fig. 10A).  U2OS cells transiently 
overexpressed with HA-tagged PRODH (Wt, L441P, or R453C) were 
immunostained with anti-H2AX and anti-HA antibodies (Fig. 10B).  The 
cells overexpressing Wt-PRODH exhibited an increased number of H2AX 
foci as compared with the cells expressing PRODH mutants, suggesting that 
the enzymatic activity of PRODH facilitated DNA damage. 
  Overall, these results showed that, upon the treatment with low doses of 
etoposide, upregulation of PRODH by p53 led to ROS accumulation, which in 
turn enhanced the DDR signaling and ultimately established senescence. 
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Discussion 
 
  DNA-damaging anticancer drugs such as etoposide and bleomycin can 
induce both senescence and apoptosis.23, 24  Although this demonstrates that 
DNA damage is a critical initiator of senescence and apoptosis, the 
mechanism underlying the determination of the choice between senescence 
and apoptosis is currently unknown.  The results presented in this study 
indicate that treatment of cells with relatively lower doses of etoposide 
induces senescence, whereas high doses of the drug induce apoptosis.  In 
addition, I found that Chk1 activation is more prolonged in cells exposed to 
the low dose of etoposide, and that the transcriptional activity of p53, a 
downstream target of Chk1, between 24 h and 36 h after etoposide treatment 
is required for senescence induction.  In this time point, the 
phosphorylation patterns of p53 were differed between low and high doses of 
etoposide.  Consistent with this, Chk1 has been reported to phosphorylate 
p53 at multiple sites within both N- and C-terminal regions and affect p53 
transcriptional activity.43, 44  In conclusion, I reasoned that genes crucial for 
senescence induction were transcriptionally activated by p53 between 24 h 
and 36 h after etoposide treatment. 
  Comparison of gene expression profiles between cells treated with low and 
high doses of etoposide identified 20 genes that were specifically upregulated 
in senescent cells.  Among these genes, I further validated the direct 
regulation of PRODH and DAO by p53 and found that overexpression of 
PRODH, DAO, and EPN3 promoted senescence, whereas ectopic GPR172B 
inhibited senescence.  Taken together, these findings indicate that PRODH 
and DAO are generally involved in various forms of p53-dependent 
senescence, while further analysis is needed to determine whether the other 
genes contribute to the senescence program. 
  PRODH, a mitochondrial inner membrane enzyme involved in the first 
and rate-limiting step in proline catabolism, is a p53-inducible gene through 
its intronic p53 responsive elements,45, 46 and upregulation of PRODH 
results in formation of proline-dependent ROS.38  Although PRODH has 
been suggested to play a role in p53-induced apoptosis,45, 47 my results 
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clearly shows that PRODH is a crucial molecule in p53-dependent 
senescence rather than apoptosis.  I revealed that overexpression of 
wild-type PRODH, but not enzymatically inactive forms, induced senescence, 
and that genetic or pharmacological inhibition of PRODH suppressed 
etoposide-induced senescence.  Moreover, ectopic expression of PRODH 
increased intracellular ROS levels, and treatment with NAC, a ROS 
scavenger, prevented senescence induced by PRODH overexpression.  It is 
widely accepted that ROS are involved in senescence.7-9, 39  ROS levels 
increase in both replicative and premature senescence, and treatment of 
cells with a sublethal dose of H2O2 induces senescence.4  ROS are 
considered to mediate senescence through induction of DNA damage, and a 
recent study has reported that a positive feedback loop between ROS 
production and the DDR establishes senescence, with a contribution of p21.48  
Consistent with this, I showed that PRODH overexpression induced DNA 
damage as confirmed by H2AX immunostaining, indicating that PRODH 
upregulated by p53 in response to senescence-inducing stresses amplifies 
DNA damage through ROS generation, thereby inducing senescence. 
  Senescence is now considered to play a critical role in tumor-suppression 
as well as aging-related disorders in various tissues resulting from a 
permanent loss of proliferation capacity.7-9  In accordance with the 
important role of PRODH in senescence, PRODH has been suggested to act 
as a tumor suppressor in vitro and in vivo.  Overexpression of PRODH 
suppresses tumorigenesis through induction of cell cycle arrest in a mouse 
xenograft model.49  Furthermore, the protein level of PRODH is reduced in 
a variety of human tumor tissues as assessed by immunohistochemistry.49  
PRODH is located in chromosome 22q11.2, a region that is often deleted in 
various human tumors, and patients harboring this deletion 
(DiGeorge/velocardiofacial syndrome) show a higher frequency of 
malignancy.50, 51  On the other hand, the relationship between PRODH and 
aging-related disorders has yet to be described.  Studies in mouse models 
are needed to determine whether PRODH has roles in senescence and aging 
as well as tumor-suppression in vivo.  PRODH-deficient and 
-overexpressing mouse strains have been described and may be useful 
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models for investigating the possible involvement of PRODH in these 
biological processes.52, 53  Regardless of their outcome, this study establishes 
the role of PRODH as an inducer of p53-dependent senescence, which may 
provide important insight into PRODH function in various processes 
including cancer and aging. 
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Figures 
 
Fig. 1.  Senescence is induced by the low dose of etoposide, whereas 
apoptosis is triggered at higher doses in HepG2 cells. 
 
Fig. 2.  Expression of DDR-related proteins in HepG2 cells treated with the 
low and high doses of etoposide. 
 
Fig. 3.  The low dose of etoposide and bleomycin induces senescence, while 
apoptosis is caused by the higher dose of etoposide in U2OS cells. 
 
Fig. 4.  ATM/ATR and Chk1 are required for etoposide-induced senescence. 
 
Fig. 5.  p53 transcriptional activation between 24 h and 36 h after 
treatment with the low dose of etoposide is required for senescence 
induction. 
 
Fig. 6.  PRODH and DAO are identified as direct transcriptional targets of 
p53. 
 
Fig. 7.  PRODH, DAO, and EPN3 promote senescence, whereas GPR172B 
suppresses senescence. 
 
Fig. 8.  PVRL4, PRODH, LY6D, DAO, EPN3, and GPR172B are 
upregulated during replicative senescence in Hs68 cells. 
 
Fig. 9.  PRODH induces senescence via ROS production. 
 
Fig. 10.  Overexpression of PRODH causes DNA damage. 
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Fig. 1.  Senescence is induced by the low dose of etoposide, whereas 
apoptosis is triggered at higher doses in HepG2 cells.  (A) HepG2 cells were 
treated with 10 or 50 M etoposide for 24 or 48 h and observed under 
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microscope.  Bars, 50 m.  (B) HepG2 cells were treated with 10 M 
etoposide for 3, 6, or 24 h and replated in 35-mm dish at 10000 cells per well.  
The cells were cultured in the medium without etoposide for 10 days and 
stained with crystal violet.  (C and D) HepG2 cells treated with 10, 50, or 
100 M etoposide for indicated times were subjected to SA--Gal staining.  
Representative images after 48 h treatment (C) and the percentage of 
SA--Gal-positive cells (D) are shown.  Bars, 50 m.  (E) HepG2 cells 
treated with 10, 50, or 100 M etoposide for 24 or 48 h were subjected to 
Annexin V staining.  Data are mean ± SD.  Statistical significance is 
shown using the Student’s t-test analysis; *P < 0.05; **P < 0.01. 
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Fig. 2.  Expression of DDR-related proteins in HepG2 cells treated with the 
low and high doses of etoposide.  Lysates from HepG2 cells treated with 10, 
50, or 100 M etoposide for indicated times were subjected to immunoblot 
analysis using antibodies as indicated.  Arrowheads indicate the cleaved 
form of the respective proteins. 
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Fig. 3.  The low dose of etoposide and bleomycin induces senescence, while 
apoptosis is caused by the higher dose of etoposide in U2OS cells.  (A) U2OS 
cells treated with 2 M etoposide or bleomycin for 1, 2, 3, 5, or 7 days were 
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replated in 35-mm dish at 1000, 5000, or 10000 cells per well.  The cells 
were cultured in the medium without drugs for 10 days and stained with 
crystal violet.  (B) U2OS cells treated with 2 M etoposide or bleomycin for 
3, 5, or 7 days were subjected to SA--Gal staining.  (C) U2OS cells treated 
with 5 or 100 M etoposide for 48 h were subjected to PI staining followed by 
flow cytometry.  (D) Lysates from U2OS cells treated with 2 or 100 M 
etoposide for 12, 24, 36, or 48 h were subjected immunoblot analysis.  Data 
are mean ± SD.  Statistical significance is shown using the Student’s 
t-test analysis; **P < 0.01. 
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Fig. 4.  ATM/ATR and Chk1 are required for etoposide-induced senescence.  
(A) (Upper panels) HepG2 cells pretreated with CGK733, an ATM/ATR 
inhibitor, at indicated doses for 1 h were treated with 10 M etoposide for 48 
h, and were subjected to immunoblot analysis.  Drug inhibition of ATM/ATR 
was shown by abrogation of p53 phosphorylation at Ser15 (an ATM/ATR 
target site) and Chk1 phosphorylation at Ser345 (an ATR target site).  
(Lower panel) HepG2 cells pretreated with 2 M CGK733 for 1 h were then 
treated with 10 or 50 M etoposide for 48 h and subjected to SA--Gal 
staining.  (B) (Upper panel) HepG2 cells pretreated with KU-55933, an 
ATM inhibitor, at indicated doses for 1 h were then treated with 10 M 
etoposide for 48 h, and were subjected to immunoblot analysis.  Drug 
inhibition of ATM was shown by abrogation of p53 phosphorylation at Ser15.  
(Lower panel) HepG2 cells pretreated with 10 M KU-55933 for 1 h were 
then treated with 10 or 50 M etoposide for 48 h and subjected to SA--Gal 
staining.  (C) HepG2 cells were transfected with siRNAs for negative 
control (Control) or ATM (ATM_1, ATM_2, ATM_3, and ATM_4).  After 
incubation for 48 h, the cells were treated with 10 M etoposide for 48 h and 
subjected to immunoblot analysis (upper panels) and the percentage of 
SA--Gal-positive cells was quantified (lower panel).  (D) (Upper panels) 
U2OS cells were transfected with siRNAs for negative control (Control) or 
Chk1 (Chk1_1, Chk1_2, Chk1_3, and Chk1_4).  After incubation for 48 h, 
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Chk1 expression was determined by immunoblot analysis.  The protein 
level relative to the α-tubulin level was quantified using NIH ImageJ 
software and is indicated at the bottom of each lane.  (Lower panel) 
Chk1-depleted cells were treated with 2 M bleomycin for 7 days and 
subjected to SA--Gal staining.  (E) (Left panels) U2OS cells transfected 
with pcDNA3-Flag containing wild-type (WT) or S345A Chk1 were selected 
with 800 g/ml G418 for 5 days.  The cells were then treated with 5 M 
etoposide for 48 h and subjected to immunoblot analysis.  Arrowhead and 
arrows indicate endogenous and exogenous Chk1, respectively.  (Right 
panel) U2OS cells overexpressing WT or S345A Chk1 were treated with 2 
M etoposide for 7 days and subjected to SA--Gal staining.  Data are mean 
± SD.  Statistical significance is shown using the Student’s t-test analysis; 
*P < 0.05; **P < 0.01. 
 61 
 
 
 
Fig. 5.  p53 transcriptional activation between 24 h and 36 h after 
treatment with the low dose of etoposide is required for senescence induction.  
(A) HepG2 cells transfected with siRNAs for p53 (p53_1, p53_2, p53_3, and 
p53_4) were treated with 10 M etoposide for 48 h, and the expression levels 
of p53 and p21 were determined by immunoblot analysis (left panels), and 
the percentage of SA--Gal-positive cells was quantified (right panel).  (B) 
HepG2 cells were treated with 10 M etoposide for various times (24, 30, 36, 
and 42 h), and then Act D was added to the medium at a concentration of 50 
ng/ml.  After 6 h of incubation in the presence of Act D and etoposide, the 
drugs were washed out by replacing the medium, and the cells retreated only 
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with etoposide up to for 48 h after initial exposure to etoposide were 
subjected to SA--Gal staining.  (C) Lysates from HepG2 cells treated with 
10 or 100 M etoposide for 24 h were subjected to Phos-tag SDS-PAGE and 
immunoblotted with the anti-p53 antibody.  Blue and red arrows indicate 
the bands showing stronger signals at 10 and 100 M etoposide, respectively.  
Asterisks indicate the bands with no difference between low and high doses 
of etoposide.  Data are mean ± SD.  Statistical significance is shown 
using the Student’s t-test analysis; *P < 0.05; **P < 0.01. 
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Fig. 6.  PRODH and DAO are identified as direct transcriptional targets of 
p53.  (A) HepG2 cells transfected with siRNAs for p53 (p53_1 and p53_2) 
were treated with 10 M etoposide for 30 h, and the expression levels of 
indicated genes were determined by qPCR.  (B) HepG2 cells treated with 10 
M etoposide for 30 h were subjected to ChIP assay with the anti-p53 
antibody or normal mouse IgG.  The fold enrichment of p53 over IgG was 
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determined by qPCR.  (C) HepG2 cells were transfected with siRNAs for 
negative control (Control) or p53 (p53_1 and p53_2).  After incubation for 48 
h, the cells were treated with 10 M etoposide for 30 h, and the levels of 
indicated proteins were determined by immunoblot analysis.  The protein 
levels relative to the -tubulin level were quantified using NIH ImageJ 
software and are indicated at the bottom of each lane.  (D) U2OS and 
SaOS-2 cells were treated with 2 M etoposide for 1, 2, 3, or 5 days, and the 
levels of indicated proteins were determined by immunoblot analysis.  The 
protein levels relative to the -tubulin level were quantified using NIH 
ImageJ software and are indicated at the bottom of each lane.  Protein 
levels at day 0 in U2OS and SaOS-2 cells were normalized to 1, respectively.  
Data are mean ± SD.  Statistical significance is shown using the Student’s 
t-test analysis; *P < 0.05; **P < 0.01. 
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Fig. 7.  PRODH, DAO, and EPN3 promote senescence, whereas GPR172B 
suppresses senescence.  (A) U2OS cells transfected with pcDNA3-HA 
containing p21, PRODH, DAO, GPR172B, PVRL4, EPN3, or LY6D were 
subjected to immunoblot analysis with the anti-HA antibody.  (B and C) 
U2OS cells transfected as described in (A) were selected with 800 g/ml 
G418 and treated with 2 M etoposide for 48 h.  The treated cells were 
cultured in the medium without etoposide for additional 5 days and 
subjected to SA--Gal staining (B) or were replated at 5000 cells per 35-mm 
dish and stained with crystal violet after 7 days of cultivation without 
etoposide (C).  The number of colonies was counted using NIH ImageJ 
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software.  Data are mean ± SD.  Statistical significance is shown using 
the Student’s t-test analysis; **P < 0.01. 
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Fig. 8.  PVRL4, PRODH, LY6D, DAO, EPN3, and GPR172B are 
upregulated during replicative senescence in Hs68 cells.  (A) Hs68 cells at 
passage numbers 30, 58, and 65 (P30, P58, and P65) were subjected to 
SA--Gal staining.  The percentage of SA--Gal-positive cells (upper panel) 
and representative images (lower panels) are shown.  Bars, 50 m.  (B) 
The mRNA level of indicated genes was determined by qPCR.  Data are 
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mean ± SD.  Statistical significance is shown using the Student’s t-test 
analysis; *P < 0.05; **P < 0.01. 
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Fig. 9.  PRODH induces senescence via ROS production.  (A) U2OS cells 
transfected with siRNA for PRODH were treated with 2 M etoposide for 5 
days and subjected to immunoblot analysis.   (B) PRODH-depleted cells 
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treated with 2 M etoposide for 7 days were subjected to SA--Gal staining.  
(C) U2OS cells transfected with pcDNA3-HA-PRODH were treated with 2 
M etoposide for 48 h, and the ROS level was measured.  (D) U2OS cells 
transfected with pcDNA3-HA-p21 or pcDNA3-HA-PRODH were selected 
with G418 and treated with 2 M etoposide in the presence of 5 mM NAC.  
After incubation for 7 days, the cells subjected to SA--Gal staining.  (E) 
U2OS cells were treated with 2 M etoposide and 5 mM L-THFA as indicated 
for 30 h and ROS levels were measured.  (F) U2OS cells cultured as 
described in (D) using 5 mM L-THFA instead of NAC, were subjected to 
SA--Gal staining.  (G) U2OS cells transfected with pcDNA3-HA containing 
wild-type (Wt), L441P, or R453C PRODH were subjected to immunoblot 
analysis.  (H) U2OS cells transfected as described in (G) were cultured for 
30 h, and the ROS level was measured.  (I) U2OS cells transfected as 
described in (G) were selected with G418 and treated with 2 M etoposide.  
After incubation for 7 days, the cells were subjected to SA--Gal staining.  
Data are mean ± SD.  Statistical significance is shown using the Student’s 
t-test analysis; *P < 0.05; **P < 0.01. 
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Fig. 10.  Overexpression of PRODH causes DNA damage.  (A) U2OS cells 
transfected with pcDNA3-HA-Wt-PRODH were treated with 2 M etoposide 
for 24 h.  The cells were then incubated with 250 nM MitoTracker for 30 
min and observed under fluorescence microscope after immunostaining for 
HA and Hoechst staining.  Bars, 10 m.  (B) U2OS cells overexpressing Wt, 
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L441P, or R453C PRODH were immunostained with anti-H2AX and 
anti-HA antibodies.  Representative microscopic images (left panels) and 
box plots of the number of H2AX foci in HA-PRODH-expressing cells (right 
panel) are shown.  DMSO and 2 M etoposide were used as negative and 
positive controls, respectively.  Statistical significance is shown using the 
Student’s t-test analysis; **P < 0.01. 
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Table 1.  List of primers used for plasmid constructions, qPCR, and 
ChIP-qPCR. 
Gene 
 
Forward 
 
Reverse 
 (For plasmid constructions) 
Chk1 (Wt) gctaacgaattcatggcagtgccctttgtgga 
cgagcattgcggccgctcatgtggcaggaagcc
aaatct 
Chk1 (S345A) 
gtacaagggatcagctttgctcagcccacatgt
cctgat 
atcaggacatgtgggctgagcaaagctgatcc
cttgtac 
PVRL4 
cgtggatcgaattcatgcccctgtccctgggagc
cgagat 
cgtgctcggcggccgctcagaccaggtgtcccc
gcccatt 
PRODH (Wt) gcgaattcaccatggctctgaggcgcgc cgtctcgagctaggcagggcgatggaag 
PRODH (L441P) 
ggtgttttggggccaagcccgtgcggggcgcat
acctg 
caggtatgcgccccgcacgggcttggccccaaa
acacc 
PRODH (R453C) 
gcatacctggcccaggagcgagcctgtgcggc
agagatcg 
cgatctctgccgcacaggctcgctcctgggccag
gtatgc 
LY6D 
cgtgctcggaattcatgaggacagcattgctgc
t 
cgtgctcggcggccgctcacaggctgggggcta
aga 
DAO 
cgtgctcggaattcatgcgtgtggtggtgattg
gag 
cgtgctcggcggccgctcagaggtgggatggtg
gcatt 
EPN3 gtatctatgaattcatgacgacctccgcactccg 
gtatctatgcggccgctcagaggaaggggttg
gtgcc 
GPR172B cgtgctcggaattcatggcagcacccacgct 
cgtgataggcggccgctcaggggccacagggg
t 
   
(For qPCR) 
GAPDH 
 
caatgaccccttcattgacct 
 
atgacaagcttcccgttctc 
 PVRL4 
 
ctgccatgtcagcaatgagt 
 
tcctgggggtcaagaacat 
 LY6D 
 
tggaatgctgatgacttggag 
 
acagaaggagtgtgaaatccg 
 GPR172B 
 
ttgctgttgccatcactacc 
 
caaagcctcttcttcctccttc 
 DAO 
 
ccactggacataaaggtctacg 
 
gggttgttggggtcagaaag 
 LOXL4 
 
ccaaagactggacgcgata 
 
aggaggtcgtagtgggtgaa 
 EVL 
 
gcctgtgtcctcgattctgt 
 
tcttagcttcggggctcttt 
  
 74 
Table 1.  List of primers used for plasmid constructions, qPCR, and 
ChIP-qPCR (Continued). 
Gene 
 
Forward 
 
Reverse 
 (For qPCR) 
PRODH 
 
catcgaagcctcaggtagagt 
 
ccccagtgctgtgagcttaat 
 E2F7 
 
tccagattcccaggaacaac 
 
tggttttggagacgaggaac 
 CRABP2 
 
tgcgcaccacagagattaac 
 
cccatttcaccaggctctta 
 IER5 
 
ttacagacagaagcccgaagt 
 
tcagctcccccaacctttat 
 E2F2 
 
tgaaggagctgatgaacacg 
 
agcacggatatcctggtaagtc 
 IGFBP2 
 
tgcaagatgtctctgaacgg 
 
cattgtagaagagatgacactcgg 
 ANGPTL2 
 
acagcacaaagaacaactcctc 
 
ttcggaaaacagaatccagc 
 NXPH4 
 
ctttccccgcagctttaat 
 
ggacaggccgaggtttttag 
 APOBEC3B 
 
cctggttccttctttgcagtt 
 
tgtgttctcctgaaggaacg 
 SLC48A1 
 
ggcagttctcgagctatctgatta 
 
ggcacaactgaactagcgga 
 PPM1D 
 
ggaggtgacacaggaccataa 
 
cgattcaccccagacttgttc 
 CCDC74B 
 
gctttgagctacccgcat 
 
caggcctaaaagtagcggaagt 
 EPN3 
 
cttggctgacatcttcgtacct 
 
tgtgttcggcctaaaacctg 
 WBSCR27 
 
tgatagtcggtgccctcagt 
 
ccttgtattgaaggttggacg 
 p21 
 
cgactgtgatgcgctaatg 
 
tctcggtgacaaagtcgaag 
 BTG2 
 
agcctcatggtctcatgctta 
 
cagctcaggggttttgttg 
 SULF2 
 
cgaccacggttaccacatc 
 
ggaccctgatgtcaaactcata 
   
(For ChIP-qPCR) 
GAPDH tactagcggttttacgggcg tcgaacaggaggagcagagagcga 
PVRL4 cttcaccaaaatgtagtcagttcc ctccttgaaagttgggcttgt 
PRODH ttgcctcagcatgtcgg caaaacagccaatcgcaag 
LY6D tgagcaaggaacttcggc cagaaatgacacctgggagag 
DAO cagtgaggagacaataaggcaa gagttggttaatcctaatcgaacct 
EPN3 caacttgtctgggcttgtatga aggccaattttccttcctgt 
GPR172B atgctctttggggcctacc cacttgctccaggggacac 
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Table 2.  Relative mRNA levels in HepG2 cells treated with 10 or 100 M 
etoposide for 30 h. 
  Microarray results (Fold change)  qPCR results (Fold change ± SD) 
Gene 10 M/DMSO 100 M/DMSO 10 M/100 M   10 M/DMSO 100 M/DMSO Molecular class 
PVRL4 32.09 14.46 2.22  22.30 ± 0.74 15.37 ± 0.65 Adhesion molecule 
GPR172B 19.25 9.57 2.01  45.13 ± 1.24 23.71 ± 1.39 G protein coupled receptor 
DAO 13.55 6.62 2.05  15.69 ± 2.62 9.46 ± 0.93 Oxidase 
CCDC74B 9.47 2.81 3.37  1.56 ± 0.13 1.58 ± 0.10 Unclassified 
LOXL4 8.66 3.39 2.55  5.41 ± 0.32 2.95 ± 0.38 Oxidase 
EVL 8.65 4.11 2.10  16.36 ± 1.39 3.65 ± 0.08 Cytoskeletal protein 
PRODH 8.42 3.71 2.27  8.62 ± 0.57 3.66 ± 0.46 Dehydrogenase 
E2F7 7.94 1.21 6.56  7.59 ± 0.74 1.63 ± 0.02 Transcription regulation 
LY6D 7.45 1.58 4.72  6.66 ± 0.23 1.80 ± 0.06 Adhesion molecule 
IGFBP2 7.30 3.48 2.10  33.60 ± 1.54 10.75 ± 0.23 Secreted polypeptide 
CRABP2 7.16 1.89 3.79  1.11 ± 0.14 1.44 ± 0.16 Transcription regulation 
EPN3 6.41 3.07 2.09  6.98 ± 0.47 3.17 ± 0.32 Unclassified 
APOBEC3B 4.99 1.22 4.09  5.96 ± 0.24 1.57 ± 0.16 RNA binding protein 
IER5 3.85 1.80 2.14  3.66 ± 0.20 1.97 ± 0.05 Transcription regulation 
ANGPTL2 3.63 1.76 2.06  3.00 ± 0.38 1.88 ± 0.13 Secreted polypeptide 
SLC48A1 3.50 1.37 2.55  3.00 ± 0.11 1.61 ± 0.04 Transport/cargo protein 
WBSCR27 3.41 1.61 2.12   2.94 ± 0.07 1.79 ± 0.35 Unclassified 
E2F2 3.33 0.27 12.33  2.33 ± 0.15 0.33 ± 0.09 Transcription regulation 
NXPH4 3.09 1.54 2.01  1.11 ± 1.03 1.06 ± 0.26 Secreted polypeptide 
PPM1D 3.08 1.47 2.10  3.14 ± 0.13 1.80 ± 0.09 Serine/threonine phosphatase 
p21 7.94 7.07 1.12  6.40 ± 0.54 5.43 ± 0.27 Cell Cycle control 
BTG2 10.13 6.82 1.49  7.92 ± 0.81 7.17 ± 0.68 Transcription regulation 
SULF2 19.37 9.78 1.98   10.60 ± 0.08 6.87 ± 0.09 Sulfatase 
Twenty genes identified to be differentially upregulated at the low dose of 
etoposide using microarray analysis.  Differential upregulation of genes in 
bold type were confirmed also by qPCR. 
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Table 3.  Relative mRNA levels of identified genes in U2OS and SaOS-2 
cells treated with 2 M etoposide (Eto) or bleomycin (BLM) for 7 days. 
 Fold change ± SD 
 U2OS cells  SaOS-2 cells 
Gene Eto/DMSO BLM/DMSO   Eto/DMSO BLM/DMSO 
PVRL4 8.27 ± 0.18 9.36 ± 0.48  1.77 ± 0.35 3.16 ± 0.07 
PRODH 4.59 ± 0.16 6.85 ± 0.46  0.17 ± 0.09 0.55 ± 0.16 
LY6D 4.10 ± 1.34 4.92 ± 0.84  0.57 ± 0.78 3.39 ± 2.07 
DAO 3.92 ± 0.28 3.93 ± 0.62  0.55 ± 0.35 1.63 ± 0.09 
EPN3 3.83 ± 0.46 4.39 ± 0.85  0.14 ± 0.07 0.17 ± 0.06 
p21 3.47 ± 0.06 3.69 ± 0.01  1.13 ± 0.02 1.28 ± 0.02 
GPR172B 2.53 ± 0.03 3.04 ± 0.05  0.83 ± 0.15 1.57 ± 0.08 
IGFBP2 2.48 ± 0.60 2.20 ± 0.29  2.88 ± 0.33 2.32 ± 0.41 
E2F7 1.92 ± 0.20 1.33 ± 0.03  1.77 ± 0.07 1.38 ± 0.08 
PPM1D 1.39 ± 0.01 1.53 ± 0.04  0.70 ± 0.00 0.80 ± 0.02 
SLC48A1 1.37 ± 0.07 1.06 ± 0.03  1.13 ± 0.09 1.33 ± 0.05 
APOBEC3B 1.00 ± 0.01 1.44 ± 0.07  1.30 ± 0.11 1.26 ± 0.02 
IER5 0.85 ± 0.02 0.74 ± 0.01  1.53 ± 0.02 1.51 ± 0.05 
ANGPTL2 0.68 ± 0.02 0.67 ± 0.02  0.28 ± 0.02 0.50 ± 0.00 
E2F2 0.24 ± 0.08 0.24 ± 0.03  1.32 ± 0.03 0.87 ± 0.11 
LOXL4 0.14 ± 0.01 0.18 ± 0.01   0.81 ± 0.02 1.57 ± 0.05 
EVL N/D N/D  N/D N/D 
WBSCR27 N/D N/D  N/D N/D 
The level of p21 served as a marker for p53-dependent DNA damage 
responses.  N/D, not detected. 
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Conclusions 
 
The results presented in this study provide insight into the molecular 
mechanisms that coordinate cell cycle progression, the DDR, and senescence.  
The results obtained from this study are as follows. 
 
Chapter I 
 
 The level of Cyclin I protein oscillates during the cell cycle. 
 Cyclin I is degraded by the ubiquitin-proteasome pathway. 
 Cyclin I forms a complex with Cdk5. 
 Cyclin I plays a role in cell cycle progression at S/G2/M phases. 
 
Chapter II 
 
 Senescence is induced by the low dose of etoposide, whereas apoptosis is 
triggered at the higher dose. 
 Six genes (PVRL4, PRODH, LY6D, DAO, EPN3, and GPR172B) are 
upregulated during senescence in p53-dependent manner.  
 PRODH and DAO are directly upregulated by p53. 
 PRODH, DAO, and EPN3 promote senescence, while GPR172B 
suppresses senescence. 
 PRODH induces senescence via ROS production and the following 
enhancement of the DDR. 
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